News
Athersys gets OK for German solid organ transplant clinical trial
MedCity News
March 27, 2012
Stem Cell Therapy Holds Promise for Strokes
Georgia Health News
March 21, 2012
Athersys, Inc. Announces Positive Results of MultiStem(R) Clinical Trial for Hematopoietic Stem Cell Transplant Support and Prevention of Graft-Versus-Host Disease
BioSpace
February 2, 2012
One-Year Follow-Up Results From Athersys' Phase I Study of MultiStem in Heart Attack Patients Presented at International Stem Cell Symposium
International Drug Discovery
June 13, 2011
Researchers From Case Western Reserve and Athersys Publish Landmark Study Showing Regenerative Benefit of MultiStem Therapy After Spinal Cord Injury
Download the PDF
January 19, 2011
Athersys
Cleveland, OH
Nasdaq: ATHX
Athersys is a biopharmaceutical and regenerative medicine company that has established a pipeline of therapeutic product development programs in multiple disease areas. The company’s product portfolio consists of MultiStem, a non-embryonic stem cell-based approach for treating certain inflammatory disorders, cardiovascular disorders, stroke, and bone marrow transplantation and oncology support.